Pharmacotherapy for Cardiovascular Disorders 6521
Case study: Patient AO has a history of obesity and has recently gained 9 pounds. The patient has been diagnosed with hypertension and hyperlipidemia. Drugs currently prescribed include the following:
Atenolol 12.5 mg daily
Doxazosin 8 mg daily
Hydralazine 10 mg qid
Sertraline 25 mg daily
Simvastatin 80 mg daily
- Select one the following factors: genetics, gender, ethnicity, age, or behavior factors.
- Reflect on how the factor you selected might influence the patient’s pharmacokinetic and pharmacodynamic processes.
- Consider how changes in the pharmacokinetic and pharmacodynamic processes might impact the patient’s recommended drug therapy.
- Think about how you might improve the patient’s drug therapy plan based on the pharmacokinetic and pharmacodynamic changes. Reflect on whether you would modify the current drug treatment or provide an alternative treatment option for the patient.
Write a 2- to 3-page paper that addresses the following:
- Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.
- Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.
- Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements.
5 years ago
12
Answer(1)![blurred-text]()
![]()
Purchase the answer to view it

NOT RATED
- PSYHCOP.pdf
- PharmacotherapyforCardiovascularDisorders.docx
other Questions(10)
- project3
- Unit 3 Indivdual Project 4–5 pages (not including title and reference pages)
- Forum week 8 Kübler-Ross’s Stages of Dying Elisabeth Kübler-Ross proposed five psychological stages of dying: denial and isolation, anger, bargaining, depression, and acceptance. These stages do not occur in a specific order, and the stages often overla
- creative writing
- Unit 6: Instructor Graded Assignment
- TREVIAN
- Human Behavior Intro 2 Part Question
- On April 1, 2014, Seminole Company sold 15,000 of its 11%, 15-year, $1,000 face value bonds at 97.
- Program Outcome 5 Demonstration Discussion 2
- Question for AW
